×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Therapeutic: Cross-Disease Therapeutic Targets in 4R-Tauopathies
therapeutic
1,704 words
KG: Cross-Disease Therapeutic Targets in 4R-Tauopathies
2026-03-24
kind:therapeutic
section:therapeutics
state:published
Contents
Cross-Disease Therapeutic Targets in 4R-Tauopathies
💊
Therapeutic Info
Name
Cross-Disease Therapeutic Targets in 4R-Tauopathies
Summary
Comparison of therapeutic targets across PSP, CBD, AGD, GGT, and FTDP-17
Knowledge Graph
Related Hypotheses (25)
Bacterial Enzyme-Mediated Dopamine Precursor Synthesis
Score: 0.36
SASP-Mediated Complement Cascade Amplification
Score: 0.70
Targeting Bacterial Curli Fibrils to Prevent α-Synuclein Cro
Score: 0.49
TREM2-mediated microglial tau clearance enhancement
Score: 0.49
Prohibitin-2 Mitochondrial Cross-Seeding Hub Disruption
Score: 0.38
Microbial Inflammasome Priming Prevention
Score: 0.58
TREM2 Conformational Stabilizers for Synaptic Discrimination
Score: 0.41
The Mitochondrial-Lysosomal Metabolic Coupling Dysfunction
Score: 0.40
TFEB-PGC1α Mitochondrial-Lysosomal Decoupling
Score: 0.40
TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegen
Score: 0.64
TREM2-Mediated Astrocyte-Microglia Cross-Talk in Neurodegene
Score: 0.61
Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming
Score: 0.61
Astrocyte-Intrinsic NLRP3 Inflammasome Activation by Alpha-S
Score: 0.60
Glymphatic-Mediated Tau Clearance Dysfunction
Score: 0.55
Dual-Circuit Tau Vulnerability Cascade
Score: 0.50
Dopaminergic Ventral Tegmental-Hippocampal Circuit Protectio
Score: 0.49
Cell-Type Specific TFEB Modulation
Score: 0.48
TREM2-Dependent Microglial Senescence Transition
Score: 0.69
APOE-Dependent Autophagy Restoration
Score: 0.61
Cell-Type Specific TREM2 Upregulation in DAM Microglia
Score: 0.52
APOE-TREM2 Interaction Modulation
Score: 0.48
Cross-Seeding Prevention Strategy
Score: 0.45
TREM2-Mediated Selective Aggregate Clearance Pathway
Score: 0.43
Low Complexity Domain Cross-Linking Inhibition
Score: 0.42
Designer TRAK1-KIF5 fusion proteins accelerate therapeutic m
Score: 0.35
Show 20 more
Related Analyses (30)
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · failed
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
Protein aggregation cross-seeding across neurodegenerative d
neurodegeneration · archived
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · archived
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed
Gene expression changes in aging mouse brain predicting neur
neurodegeneration · archived
Gene expression changes in aging mouse brain predicting neur
neurodegeneration · failed
Gene expression changes in aging mouse brain predicting neur
neurodegeneration · failed
Gene expression changes in aging mouse brain predicting neur
neurodegeneration · failed
Gene expression changes in aging mouse brain predicting neur
neurodegeneration · archived
Immune atlas neuroinflammation analysis in neurodegeneration
Neuroinflammation · archived
Microglial subtypes in neurodegeneration — friend vs foe
neuroscience · failed
Cell type vulnerability in Alzheimer's Disease (SEA-AD data)
neurodegeneration · failed
Cell type vulnerability in Alzheimer's Disease (SEA-AD data
neurodegeneration · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · failed
Metabolic reprogramming in neurodegenerative disease
neurodegeneration · completed
TREM2 Therapeutic Strategy Post-INVOKE-2
neurodegeneration · completed
GBA-Synuclein Loop Therapeutics for PD
neurodegeneration · completed
Gut-Brain Axis Therapeutics for AD
neurodegeneration · completed
Show 25 more
Related Experiments (14)
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Tau depletion effects on neuronal development in primary cul
exploratory · proposed · Score: 0.90
RBG treatment in ApoE-/- atherosclerosis mouse model
validation · proposed · Score: 0.90
Trehalose-induced lysosomal changes and TFEB activation
exploratory · proposed · Score: 0.90
Leukocyte gene expression analysis in COVID-19 patients
exploratory · proposed · Score: 0.90
Trehalose-induced lysosomal membrane permeabilization and TF
exploratory · proposed · Score: 0.90
Functional validation of trehalose effects on misfolded prot
exploratory · proposed · Score: 0.85
Microtubule domain analysis in adult axons
exploratory · proposed · Score: 0.80
NLRP3 Inflammasome Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
Pre-Symptomatic Tau Detection in MAPT Mutation Carriers
clinical · proposed · Score: 0.40
Microglial TREM2 Agonist In Vivo Efficacy
validation · proposed · Score: 0.40
TREM2 Agonist Therapy for Parkinson's Disease — Experimental
validation · proposed · Score: 0.40
TREM2 Function in Alzheimer's Disease — From Risk Variant to
validation · proposed · Score: 0.40
Mouse Cdk5, p35, and p39 mutations in neuronal migration
validation · proposed · Score: 0.80
Show 9 more
See Also (15)
Tau Seeding and Propagation Pathway
mechanism · Pages share 4 hypotheses
Transdiagnostic Proteomic Changes in Neurodegeneration
mechanism · Pages share 3 hypotheses
Transdiagnostic Proteomic Changes in Neurodegeneration
mechanism · Pages share 3 hypotheses
Therapeutic Targets in Neurodegeneration
mechanism · Pages share 3 hypotheses
Synaptic Loss in Alzheimer's Disease Pathway
mechanism · Pages share 3 hypotheses
Sex Differences in Neurodegeneration
mechanism · Pages share 3 hypotheses
Senescent Cell Clearance in Neurodegeneration
mechanism · Pages share 3 hypotheses
Retinal Degeneration Pathway in Neurodegeneration
mechanism · Pages share 3 hypotheses
Neuroinflammation Hypothesis in Alzheimer's Disease
mechanism · Pages share 3 hypotheses
Neuroimmune Interface Pathway
mechanism · Pages share 3 hypotheses
Neural Circuit Disruption in Neurodegeneration
mechanism · Pages share 3 hypotheses
msa-pathophysiology-disease-mechanisms
mechanism · Pages share 3 hypotheses
MSA Glial Pathology — Detailed Comparison with Parkinso
mechanism · Pages share 3 hypotheses
Microglial Priming Pathway in Neurodegeneration
mechanism · Pages share 3 hypotheses
Lipid Metabolism Dysregulation in Neurodegeneration
mechanism · Pages share 3 hypotheses
Show 10 more